.Pharmacolibrary.Drugs.ATC.N.N05AE05

Information

Lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia and bipolar depression in adults and adolescents. It acts primarily as an antagonist at dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors. Lurasidone is currently approved and widely used.

Pharmacokinetics

Pharmacokinetic parameters for lurasidone in healthy adult subjects after oral administration. Data mainly reflect single-dose administration of 40 mg under fed conditions.

References

1. Hu, C, et al., & Jia, J (2017). Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects. Clinical drug investigation 37(9) 861–871. DOI:10.1007/s40261-017-0546-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28695535

2. Rado, J, & Janicak, PG (2012). Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. Drugs & aging 29(10) 783–791. DOI:10.1007/s40266-012-0009-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23018584

3. McGrane, IR, et al., & Munjal, RC (2021). Roux-en-Y Gastric Bypass and Antipsychotic Therapeutic Drug Monitoring: Two Cases. Journal of pharmacy practice 34(3) 503–506. DOI:10.1177/0897190020905467 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32067562

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)